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Risk of neuropsychiatric adverse events associated with 
varenicline: systematic review and meta-analysis
Kyla H Thomas, Richard M Martin, Duleeka W Knipe, Julian P T Higgins, David Gunnell
AbstrAct
ObjeCtive
To determine the risk of neuropsychiatric adverse 
events associated with use of varenicline compared 
with placebo in randomised controlled trials.
Design
Systematic review and meta-analysis comparing study 
effects using two summary estimates in fixed effects 
models, risk differences, and Peto odds ratios.
Data sOurCes
Medline, Embase, PsycINFO, the Cochrane Central 
Register of Controlled Trials (CENTRAL), and 
clinicaltrials.gov.
eligibility Criteria fOr seleCting stuDies
Randomised controlled trials with a placebo 
comparison group that reported on neuropsychiatric 
adverse events (depression, suicidal ideation, suicide 
attempt, suicide, insomnia, sleep disorders, abnormal 
dreams, somnolence, fatigue, anxiety) and death. 
Studies that did not involve human participants, did 
not use the maximum recommended dose of 
varenicline (1 mg twice daily), and were cross over 
trials were excluded.
results
In the 39 randomised controlled trials (10 761 
participants), there was no evidence of an increased 
risk of suicide or attempted suicide (odds ratio 1.67, 
95% confidence interval 0.33 to 8.57), suicidal 
ideation (0.58, 0.28 to 1.20), depression (0.96, 0.75 to 
1.22), irritability (0.98, 0.81 to 1.17), aggression (0.91, 
0.52 to 1.59), or death (1.05, 0.47 to 2.38) in the 
varenicline users compared with placebo users. 
Varenicline was associated with an increased risk of 
sleep disorders (1.63, 1.29 to 2.07), insomnia (1.56, 
1.36 to 1.78), abnormal dreams (2.38, 2.05 to 2.77), 
and fatigue (1.28, 1.06 to 1.55) but a reduced risk of 
anxiety (0.75, 0.61 to 0.93). Similar findings were 
observed when risk differences were reported. There 
was no evidence for a variation in depression and 
suicidal ideation by age group, sex, ethnicity, smoking 
status, presence or absence of psychiatric illness, and 
type of study sponsor (that is, pharmaceutical industry 
or other).
COnClusiOns
This meta-analysis found no evidence of an increased 
risk of suicide or attempted suicide, suicidal ideation, 
depression, or death with varenicline. These findings 
provide some reassurance for users and prescribers 
regarding the neuropsychiatric safety of varenicline. 
There was evidence that varenicline was associated 
with a higher risk of sleep problems such as insomnia 
and abnormal dreams. These side effects, however, 
are already well recognised.
systematiC review registratiOn
PROSPERO 2014:CRD42014009224.
Introduction
Smoking is the major avoidable cause of preventable 
morbidity and premature mortality in the United King-
dom and internationally.1 2 Researchers have estimated 
that smoking related illnesses cost the National Health 
Service (NHS) about £5bn (€7bn, $8bn) annually.3 
Varenicline was first licensed in the UK in 2006. Ran-
domised controlled trials have shown it to be the most 
clinically effective drug for short term abstinence in 
smoking cessation.4 Concerns about its neuropsychiat-
ric safety, however, led the Medicines and Healthcare 
Products Regulatory Agency (MHRA) to issue warnings 
about varenicline in the UK in 2008.5 Similarly, since 
2009, the United States Food and Drug Administration 
(FDA) has required the addition of a black box warning 
(the strongest safety warning that can be issued by the 
agency) to the labelling of varenicline.6 These warnings 
were based on spontaneous reports of adverse drug 
reactions from the yellow card scheme and the FDA 
adverse events reporting system.
Since the original safety warnings, several studies 
have investigated the neuropsychiatric safety of vareni-
cline.7–10 Most of the studies were observational 
cohorts,7–9 although one study examined the risk in a 
meta-analysis of 17 industry sponsored trials.10 None of 
WhAt Is AlreAdy knoWn on thIs topIc
Varenicline is a commonly prescribed and effective drug for smoking cessation. The 
Medicines and Healthcare Products Regulatory Agency (MHRA) and Food and Drug 
Administration (FDA) have issued safety warnings regarding suicidal thoughts and 
depression associated with the use of varenicline, based on reports from 
spontaneous reporting systems
Evidence from previous observational cohort studies and a meta-analysis of 17 
trials sponsored by Pfizer have found no evidence of an association with suicide, 
non-fatal self harm, or depression
Concerns have been raised about the validity of these findings as observational 
studies are prone to confounding and industry sponsored trials are more likely than 
other trials to report outcomes that are favourable to the study sponsor
WhAt thIs pAper Adds
Our meta-analysis of all published randomised controlled trials is the most 
comprehensive meta-analysis of neuropsychiatric adverse events associated with 
varenicline use to date, and reports effects using two summary statistics, a relative 
measure (Peto odds ratio) and an absolute measure (risk difference)
There was no evidence of an increased risk of suicide or attempted suicide, suicidal 
ideation, depression, or death in varenicline users compared with placebo users
Varenicline was associated with an increased risk of sleep disorders, insomnia, and 
abnormal dreams, side effects that are already well recognised and included in 
patient information leaflets for varenicline
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the studies found evidence of an increased risk of 
depression, suicide, or non-fatal self harm with vareni-
cline. Two major concerns, however, have been raised 
about the validity of these findings. Firstly, observa-
tional studies are prone to confounding by indication.11 
For example, the use of drugs for smoking cessation 
might seem to be associated with an increased risk of 
suicide because smokers themselves are at increased 
risk of mental illness and suicide.12 13 Secondly, there is 
evidence that industry sponsored trials are more likely 
than other trials to report outcomes that are favourable 
to the study sponsor.14 Though the number of prescrip-
tion items of varenicline dispensed in England 
increased from 499 in 2006 to a peak of almost a million 
in 2011, there was a 25% decrease from 2011 to 2013.15 
This might reflect ongoing fears among prescribers and 
patients regarding varenicline’s safety.
We conducted a systematic review and meta-analysis 
to determine the risk of neuropsychiatric adverse events 
and death in all published placebo controlled ran-
domised controlled trials of varenicline. This review 
deals with some of the limitations of the previous stud-
ies and is the most comprehensive published review to 
date of the neuropsychiatric safety of varenicline.
Methods
eligibility and literature search
We sought all placebo controlled randomised con-
trolled trials of any duration in humans of varenicline at 
the maximum dose (1 mg twice daily) as described in 
the recommended standard titration regimen for 
varenicline (www.chantix.com). We included studies in 
smokers and non-smokers. We conducted searches of 
computer databases and online clinical trial registries 
(Medline, Embase, PsycINFO, the Cochrane Central 
Register of Controlled Trials (CENTRAL) and clinicaltri-
als.gov). The search strategy is shown in appendix 1. 
The searches were performed from the inception of 
each of the databases to 9 May 2014. There were no lan-
guage restrictions. We manually searched reference 
lists of relevant research articles and previous system-
atic reviews.10 16
Outcome measures
Our primary outcome measures were neuropsychiatric 
adverse events comprising suicide, attempted suicide, 
suicidal ideation, and depression. Secondary outcomes 
included other neuropsychiatric outcomes (abnormal 
dreams, aggression, anxiety, fatigue, insomnia, irrita-
bility, sleep disorders, somnolence) and death. We 
included all deaths, regardless of whether or not we 
believed they were related to drug treatment.
Data extraction and management
Two reviewers (KHT and DWK) independently screened 
the identified studies by title and abstract against the 
eligibility criteria. We then obtained full reports of stud-
ies for a second round of screening. We identified dupli-
cate publications for exclusion by examining the study 
name, authors, study population, location, and the 
dates of duration of the study. A third reviewer (DG) 
reviewed all excluded studies and studies when there 
was disagreement regarding inclusion or exclusion.
KHT (all papers) and DG and RMM (papers equally 
shared) performed double data extraction to collect 
information on the study design (duration of treatment, 
description of allocation concealment, and blinding), 
study participants (inclusion and exclusion criteria, 
country, region, population studied, and baseline char-
acteristics such as ethnicity, sex, smoking history), 
description of the intervention and placebo groups, pri-
mary and secondary outcomes, measures of efficacy of 
treatment, losses to follow-up, and study sponsor. KHT 
contacted authors of all studies to verify the accuracy of 
the extracted data.
assessment of risk of bias
The Cochrane tool for assessing the risk of bias was 
used to assess whether there was high, low, or unclear 
risk of bias in the following domains: random sequence 
generation, allocation concealment, blinding of partic-
ipants and personnel, blinding of outcome assess-
ment, incomplete outcome data, selective outcome 
reporting, and other sources of bias.17 KHT (all papers) 
and DG and RMM (papers equally shared) assessed the 
risk of bias. Discrepancies were resolved by referring to 
the original publications and discussion among all 
three reviewers. KHT also contacted study authors to 
obtain study protocols and additional information that 
might not have been published to aid with assessment 
of the risk of bias.
statistical analysis
We described study characteristics according to sample 
size, characteristics of study participants, study dura-
tion, duration of treatment, and source of funding. For 
trials with more than two intervention groups, we 
extracted data for the maximum dose of varenicline 
(that is, 1 mg twice daily) and the placebo group. The 
“metan” command in Stata (version 13, StataCorp, USA) 
was used to conduct all of the meta-analyses.18 Because 
our outcomes of interest are rare, we followed recom-
mendations of Bradburn and colleagues19 and used 
Peto odds ratios to compare the varenicline and placebo 
groups. We also undertook meta-analyses using Man-
tel-Haenszel risk differences. We report results includ-
ing 95% confidence intervals and forest plots for both 
measures so that findings can be compared. Statistical 
heterogeneity was assessed with the I2 statistic.20
For sensitivity analyses, we used inverse variance 
methods under fixed and random effects models for the 
outcomes with the largest number of treatment events; 
random effects models can be problematic for 
meta-analyses of rare events.21 We report subgroup 
analyses for the primary outcomes by age (<40 v ≥40), 
sex (<50% male v ≥50% male), ethnicity (<50% white v 
≥50% white), presence or absence of psychiatric ill-
ness, smoking status (smokers including smokeless 
tobacco users v majority non-smokers (>60% 
non-smokers)), and whether or not the study was 
 sponsored by a pharmaceutical company. Studies were 
not categorised as sponsored by a pharmaceutical 
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 company if the drug was provided at no cost by the 
manufacturer and/or if the research was investigator 
initiated—that is, the drug and some funding was 
 provided by the manufacturer although there was no 
other involvement in study conduct or publication and 
data were independently held by the researchers. Tests 
for subgroup differences were performed. Funnel plot 
asymmetry was assessed for two outcome—depression 
and insomnia—with Harbord’s modified test for small 
study effects with the “metafunnel” and “metabias” 
commands in Stata.22 23
results
study characteristics
Figure 1 summarises the selection of studies. The 
search strategy identified 1089 studies from the com-
puterised databases (476 from Medline, 517 from Psy-
cINFO, and 96 from Embase). One additional trial was 
identified from CENTRAL and clinical.trials.gov. Out of 
the 1090 studies, 130 were duplicates and 905 were 
excluded based on screening of titles and abstracts; 
therefore 55 papers met the criteria for further screen-
ing. After the second round of screening, 42 trials were 
identified for further data extraction.24–65 Two addi-
tional studies were identified when the search was 
repeated for the week beginning Monday 4 August 
2014.66 67 Forty four studies were included in the sys-
tematic review. We received responses from study 
authors for 33 studies (75%).
Table 1 and appendix 2 describe study characteris-
tics. The trials included 11 146 participants (6015 
patients were randomised to receive a maximum of 
varenicline 1 mg twice daily and 5131 patients received 
a placebo). Of these randomised patients, 10 998 were 
evaluable for adverse events (5931 in the varenicline 
group and 5067 in the placebo group). The duration of 
treatment ranged from one week to 52 weeks, while 
study duration ranged from eight days to 53 weeks. 
Eighteen trials (61.3% of all participants) included 
 cigarette smokers from the general population with no 
history of psychiatric illnesses (Table 2). In trials that 
included cigarette smokers (39 trials) participants 
smoked an average of 20 cigarettes a day for 26.6 years 
in the varenicline group and 20 cigarettes a day for 26.2 
years in the placebo group. Loss to follow-up ranged 
from 0% to 60% in both groups (appendix 2). In 12 trials 
losses to follow-up were higher in the varenicline group 
than the placebo group, whereas in 17 trials losses to 
follow-up were higher in the placebo group than the 
varenicline group.
Table 3 shows the assessment of risk of bias. We 
excluded five trials from the meta-analysis as the risk of 
bias was unclear in four or more of the six domains47 52 60 
or because no data were reported in the published papers 
and the study authors did not respond to our requests for 
data.48 49 52 This resulted in exclusion of 114 patients 
(1.9%) from the varenicline group and 123 patients (2.4%) 
from the placebo group; 10 761 patients were included in 
the meta-analyses (5817 in the varenicline group and 
4944 in the placebo group). In three trials39 41 42 there 
were high losses to follow-up, 53.7%, 60%, and 45.2%, 
respectively. These studies were assessed as low risk of 
bias because of incomplete outcome data and were not 
excluded. They were all small trials (combined total of 
n=92 in the varenicline group (1.6% of all people ran-
domised to varenicline in our meta-analysis) and n=86 in 
the placebo group (1.7% of all people randomised to pla-
cebo)). In addition, only nine out of 178 patients (5.1%) 
were lost to follow-up because of adverse events, and 
these were mostly gastrointestinal in nature (such as 
nausea and vomiting).39 42 41
risk of neuropsychiatric adverse events and death
Two people died by suicide (both in the varenicline 
arms) and four attempted to do so (two in the vareni-
cline arm and two in the placebo arm). Table 4 sum-
marises the Peto odds ratios, risk differences, and 95% 
confidence interval for the primary and secondary out-
comes. Because of the small numbers of events, we 
combined suicide and attempted suicide into a single 
outcome. Thirty one trials reported suicide and suicide 
attempt; the Peto odds ratio for varenicline versus pla-
cebo was 1.67 (95% confidence interval 0.33 to 8.57; 
P=0.54, I2=10.3%) and the risk difference was 0.0003 
(−0.002 to 0.003; P=0.81, I2=0.0%). Twenty trials 
reported suicidal ideation (figs 2 and 3); the Peto odds 
ratio was 0.58 (0.28 to 1.20; P=0.14, I2=0.0%) and the 
risk difference was −0.003 (−0.009 to 0.002; P=0.24, 
I2=0.0%). Thirty one trials reported on depression (figs 
4 and 5); the Peto odds ratio was 0.96 (0.75 to 1.22; 
P=0.74, I2=0.0%) and the risk difference was −0.001 
(−0.01 to 0.01; P=0.74, I2=0.0%). Death was reported in 
36 trials (total 13/5760 in the varenicline group and 
11/4887 in the placebo group). The Peto odds ratio for 
death was 1.05 (0.47 to 2.38; P=0.9, I2=38.7%), and 
Boxes (n=)Articles identied through lit rature search on 9 May 2014
  (n=1090):
    Computerised databases (n=1089): 
      Medline (n=476), Embase (n=96), PsycINFO (n=517)
    Additional trials identied from Cochrane database of
    randomised controlled trials or Clinicaltrials.gov (n=1)
Screening of titles and abstracts (n=1090)
Full text articles for second round of screening (n=55)
Eligible trials aer second round of screening (n=42)
Included in systematic review (n=44)
Additional trials published aer search (n=2)
Drug manufacturer conrmed no further
trials underway for publication in 2014
Duplicates (n=130)
Excluded (n=905)
Excluded (n=13):
  Crossover trials (n=8)
  No monitoring of adverse events/single
    dose/<max dose varenicline (n=4)
  Second paper on same trial with no
    additional information (n=1)
fig 1 | flow chart showing selection of randomised controlled 
trials for inclusion in systematic review of varenicline
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there was no evidence of an increased risk of death in 
the varenicline group compared with the placebo 
group (risk difference 0.0001, −0.003 to 0.003; P=0.94, 
I2=0.0%) (Table 4). The forest plots for the secondary 
outcomes are shown in appendix 3.
We found no evidence of an increased risk of irritabil-
ity (odds ratio 0.98, 05% confidence interval 0.81 to 1.17; 
P=0.79, I2=0.0%), aggression (0.91, 0.52 to 1.59; P=0.75, 
I2=20.8%), or somnolence (1.23, 0.94 to 1.62; P=0.13, 
I2=10.4%) as the confidence intervals included the null 
value of 1. Varenicline was associated with an increased 
risk of sleep disorders (1.63, 1.29 to 2.07; P<0.001, 
I2=0.0%), insomnia (1.56, 1.36 to 1.78; P<0.001, I2=0.0%), 
abnormal dreams (2.38, 2.05 to 2.77; P<0.001, I2=22.3%), 
and fatigue (1.28, 1.06 to 1.55; P=0.01, I2=6.3%), with 
some evidence of a reduced risk of anxiety (0.75, 0.61 to 
0.93; P=0.008, I2=5.7%). Consistent findings were 
observed for the risk differences (table 4).
sensitivity analyses
There were minimal differences in the effect measures 
and 95% confidence intervals with Peto, fixed effects, 
and random effects odds ratios (Table 5).
subgroup analyses
The subgroup analyses are shown in appendix 4 for the 
primary outcomes of depression and suicidal ideation. 
Subgroup tests showed no evidence of a variation in the 
table 1 | Characteristics of randomised controlled trials of varenicline 1mg twice daily included in systematic review
study
Duration (weeks) sample size mean age (years) % men % white
study treatment varenicline Placebo varenicline Placebo varenicline Placebo varenicline Placebo
Anthenelli, 201324 52 12 256 269 45.4 47.1 37.9 36.8 NA NA
Bolliger, 201125 24 12 394 199 43.1 43.9 57.7 65.7 30.3 31.3
Brandon, 201126 2.2 2.2 56 58 45.8 41.2 60.9 61.1 54.1 64.8
Burstein, 200627 1.3 1.3 8 8 68.1 67.9 75 50 50 37.5
Chengappa, 201466 24 12 31 29 45.7 46.2 29 34.5 64.5 72.4
Cinciripini, 201328 24 12 86 106 43.8 45.2 61.6 63.2 58.1 71.7
Ebbert, 201129 24 12 38 38 40.7 41 100 100 100 100
Evins, 201430 64 40 40 47 51.4 45.7 60 66 75 72
Faessel, 200931 2.6 2 14 7 15.4 15.4 57.1 57.1 85.7 71.4
Fagerstrom, 201032 26 12 213 218 43.9 43.9 89 90 99 100
Fatemi, 201333 12 12 6 9 40.4 41.4 83.3 77.8 50 88.9
Garza, 201134 16 12 55 55 33.4 33.8 60 72.7 80 70.9
Gonzales, 200635 52 12 352 344 42.5 42.6 50 54.1 79.5 76.2
Gonzales, 201467 52 12 251 247 47.7 47.3 49.8 49.4 94.8 91.4
Hughes, 201136 24 8 107 111 44 41.2 60.5 57.2 91.4 91.9
Jorenby, 200637 52 12 344 341 44.6 42.3 55.2 58.1 85.5 85
Litten, 201338 16 13 97 101 46 45 73.2 68.3 61.9 70.3
McClure, 201339 5 5 54 50 45 43 40 59 32 36
McKee, 200940 1.1 1 10 10 34.2 35.3 80 80 40 90
Meszaros, 201341 12 8 5 5 42 44 80 60 40 60
Mitchell, 201242 16 12 33 31 29 25 55 65 73 64
Nakamura, 200743 52 12 156 154 40.1 39.9 79.2 76 NA NA
Niaura, 200844 40 12 160 160 41.5 42.1 50.3 53.5 93 88.4
Nides, 200645 52 7 127 127 41.9 41.6 50.4 52 85.6 87.8
Oncken, 200646 52 12 259 129 42.2 43 48.5 51.9 80.8 72.1
Plebani, 201247 9 8 18 19 NA NA 69.6 75 11 33
Plebani, 201348 13 12 19 21 44.8 48.1 78.9 90.5 42.1 71.4
Poling, 201049 12 11 13 18 36.5 34.4 84.6 77.8 46.2 72.2
Rennard, 201250 24 12 493 166 43.9 43.2 60 59.6 68 68.1
Rigotti, 201051 52 12 355 359 57 55.9 75.2 82.2 80.3 80.8
Shim, 201252 8 8 60 60 39.9 39.9 38 45 0 0
Stein, 201353 24 24 137 45 39.2 40.6 46 62.2 82.5 75.6
Steinberg, 201154 24 12 40 39 NA NA 60 59 77 67
Tashkin, 201155 52 12 250 254 57.2 57.1 62.5 62.2 81.9 84.1
Tonnesen, 201356 52 12 70 69 53.6 55.6 42.9 49.3 NA NA
Tonstad, 200657 52 12 603 607 45.4 45.3 50.2 48.3 96.7 97
Tsai, 200758 24 12 126 124 39.7 40.9 84.9 92.7 0 0
Wang, 200959 24 12 165 168 39 38.5 96.4 97 0 0
Weiner, 201160 12 12 4 5 NA NA NA NA NA NA
Williams, 200761 53 52 251 126 48.2 46.6 50.6 48.4 86.9 92.1
Williams, 201262 26 12 84 43 40.2 43 77.4 76.7 59.5 58.1
Wong, 201263 52 12 151 135 51.9 53.3 55 50.4 NA NA
Zesiewicz, 201264 8 8 10 10 47.4 53.8 44 67 NA NA
Zhao, 201165 3.7 3 14 10 71 73 42.9 50 100 90
NA=not applicable.
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side effects of depression and suicidal ideation by age 
group (P=0.391 and P=0.933, respectively, for interac-
tion), percentage of men in the study (P=0.418 and 
P=0.925), percentage of white people in the study 
(P=0.685 and P=0.254), presence or absence of psychi-
atric illness (P=0.126 and P=0.304), smoking status 
(P=0.906 for depression but not calculated for suicidal 
ideation as there were no reports of suicidal ideation in 
studies that included non-smokers), and whether the 
trial was industry sponsored or not (P=0.386 and 
P=0.380). The effect estimates (odds ratio) for the trials 
in which all participants had psychiatric illnesses com-
pared with those where none of the participants had 
psychiatric illness were 1.49 (95% confidence interval 
0.84 to 2.65) versus 0.91 (0.69 to 1.21) for depression and 
0.79 (0.32 to 1.93) versus 0.34 (0.09 to 1.29) for suicidal 
ideation.
table 2 | summary of characteristics of patients enrolled in 44 randomised controlled 
trials of varenicline
Characteristics of trial participants no of trials
Smokers from general population 18
Smokers with psychiatric illness 8
Heavy drinking smokers/alcohol dependence 4
People dependent on cocaine or opioid dependent 3
Smokeless tobacco users 2
Smokers with mild to moderate COPD 1
Smokers with cardiovascular disease 1
Smokers about to undergo surgery 1
Patients with spinocerebellar ataxia type 3 1
Adolescent smokers 1
Elderly non-smokers 1
Smokers in hospital 1
Smokers previously treated with varenicline 1
Ex-smokers on long term NRT 1
COPD=chronic obstructive pulmonary disease; NRT=nicotine replacement therapy.
table 3 | risk of bias assessment for each trial of varenicline using Cochrane risk of assessment of bias tool
study
random sequence 
generation
allocation 
concealment used
blinding
incomplete 
outcome data
selective 
reporting Other bias
Participants 
and personnel
Outcome 
assessment
Anthenelli 201324 Low Low Low Low Low Low Low
Bolliger 201125 Low Low Low Low Low Low Low
Brandon 201126 Low Low Low Low Low Low Low
Burstein 200627 Low Low Low Low Low Low Low
Chengappa 201466 Low Low Low Low Low Low Low
Cinciripini 201328 Low Low Low Low Low Low Low
Ebbert 201129 Low Unclear Low Low Low Low Low
Evins 201430 Low Low Low Low Low Low Low
Faessel 200931 Low Low Low Low Low Low Low
Fagerstrom 201032 Low Low Low Low Low Low Low
Fatemi 201333 Unclear Low Low Low Low Low Low
Garza 201134 Unclear Low Low Low Low Low Low
Gonzales 206635 Low Low Low Low Low Low Low
Gonzales 201467 Low Low Low Low Low Low Low
Hughes 201136 Low Low Low Low Low Unclear Low
Jorenby 200637 Low Low Low Low Low Low Low
Litten 201338 Low Low Low Low Low Low Low
McClure 201339 Low Low Low Low Low Low Low
McKee 200940 Unclear Unclear Low Unclear Low Low Low
Meszaros 201341 Low Low Low Low Low Low Low
Mitchell 201242 Low Low Low Low Low Low Low
Nakamura 200743 Low Low Low Low Low Low Low
Niaura 200844 Low Low Low Low Low Low Low
Nides 200645 Low Low Low Low Low Low Low
Oncken 200646 Low Low Low Low Low Low Low
Plebani 201247 Unclear Unclear Unclear Unclear Low Unclear Low
Plebani 201348 Low Low Low Unclear Unclear Unclear Low
Poling 201049 Low Unclear Low Unclear Low Low Low
Rennard 201250 Low Low Low Low Low Low Low
Rigotti 201051 Low Low Low Low Low Low Low
Shim 201252 Unclear Unclear Low Unclear Unclear Unclear Unclear
Stein 201353 Low Low Low Low Low Low Low
Steinberg 201154 Low Low Low Low Low Low Low
Tashkin 201155 Low Low Low Low Low Low Low
Tonnesen 201356 Low Unclear Low Low Low Low Low
Tonstad 200657 Low Low Low Low Low Low Low
Tsai 200758 Low Low Low Low Low Low Low
Wang 200959 Low Low Low Low Low Low Unclear
Weiner 201160 Unclear Unclear Unclear Unclear Low Unclear Unclear
Williams 200761 Low Low Low Low Low Low Low
Williams 201262 Low Low Low Low Low Low Low
Wong 201263 Low Low Low Low Low Low Low
Zesiewicz 201264 Low Low Low Low Low Low Low
Zhao 201165 Low Low Low Low Low Low Unclear
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small study effects
The funnel plots for depression and insomnia are 
shown in appendix 5. The P values for funnel plot asym-
metry were 0.53 for depression and 0.93 for insomnia 
(that is, there was no evidence against the null hypoth-
esis of no small study effects).
discussion
This meta-analysis of 39 randomised controlled trials, 
involving 5817 patients prescribed varenicline 1 mg 
twice daily and 4944 patients prescribed placebo, 
found no increased risk of suicide or attempted suicide, 
suicidal ideation, depression, or death in individuals 
treated with varenicline. Almost half of the trial partici-
pants were chronic heavy smokers (that is, they had 
smoked on average 20 cigarettes a day for 26 years). Five 
separate trials (including 1281 participants randomised 
to varenicline and 1143 to placebo) reported a suicide 
and/or suicide attempt (see appendix 3); one reported 
suicide only, three reported attempted suicide only, and 
one reported both suicide and attempted suicide. Two 
suicides and two attempts occurred in the varenicline 
group of the trials (0.08%) and two attempts occurred 
in the placebo group (0.05%). Use of the maximum dose 
of varenicline (1 mg twice daily) was associated with a 
28% increased risk of fatigue, a 56% increased risk of 
insomnia, a 63% increased risk of sleep disorders, and 
more than twice the risk of abnormal dreams. There was 
evidence of a 25% reduction in the risk of anxiety. When 
we used risk differences, for every 1000 patients there 
were an additional 10 cases of fatigue, 40 cases of 
insomnia, 20 cases of sleep disorders, and 60 cases of 
abnormal dreams in those prescribed varenicline com-
pared with placebo. Similarly, there were 10 fewer epi-
sodes of anxiety per 1000 participants in the varenicline 
group compared with the placebo group (risk difference 
−0.01, 95% confidence interval −0.02 to −0.0003). There 
was no evidence of a variation in depression and sui-
cidal ideation by age, sex, ethnicity, presence or 
absence of psychiatric illness, or type of study sponsor.
Comparison with other studies
A recent study by Kishi and Iwata examined the effects of 
varenicline for smoking cessation in people with schizo-
phrenia in a meta-analysis of seven randomised con-
trolled trials.68 With the exception of the study by Hong 
and colleagues,69 we included all their randomised con-
trolled trials in the current analysis. Similar to our find-
ings, Kishi and Iwata found no significant differences in 
depression and suicidal ideation between the vareni-
cline and placebo groups. They reported, however, that 
varenicline use was associated with a lower risk of abnor-
mal dreams/nightmares than placebo (relative risk 
0.47, 95% confidence interval 0.22 to 0.99; P=0.05).68 
table 4 | summary of Peto odds ratios, risk differences, and 95% confidence intervals for neuropsychiatric events in people treated with varenicline
neuropsychiatric adverse event
no of events/no treated
Odds ratio (95% Ci), P value risk difference (95% Ci), P valuevarenicline group Placebo group
Primary outcomes
Depression 163/5356 139/4487 0.96 (0.75 to 1.22), 0.74 −0.001 (−0.01 to 0.01), 0.74
Suicidal ideation 15/2799 18/2191 0.58 (0.28 to 1.20), 0.14 −0.003 (−0.009 to 0.002), 0.24
Attempted suicide 2/2184 2/1842 0.75 (0.10 to 5.65), 0.78 −0.0003 (−0.005 to 0.004), 0.91
Suicide and attempted suicide 4/5352 2/4478 1.67 (0.33 to 8.57), 0.54 0.0003 (−0.002 to 0.003), 0.81
secondary outcomes
Abnormal dreams 603/5606 224/4741 2.38 (2.05 to 2.77), <0.001 0.06 (0.05 to 0.07), <0.001
Aggression 39/4276 24/3524 0.91 (0.52 to 1.59), 0.75 −0.001 (−0.005 to 0.004), 0.79
Anxiety 209/4999 226/4457 0.75 (0.61 to 0.93), 0.008 −0.01 (−0.02 to −0.0003), 0.01
Death 13/5760 11/4887 1.05 (0.47 to 2.38), 0.9 0.0001 (−0.003 to 0.003), 0.94
Fatigue 283/5502 202/4701 1.28 (1.06 to 1.55), 0.01 0.01 (0.002 to 0.02), 0.01
Insomnia 679/5621 379/4762 1.56 (1.36 to 1.78), <0.001 0.04 (0.03 to 0.05), <0.001
Irritability 293/5406 266/4615 0.98 (0.81 to 1.17), 0.79 −0.001 (−0.01 to 0.008), 0.79
Sleep disorders 211/5081 123/4284 1.63 (1.29 to 2.07), <0.001 0.02 (0.01 to 0.02), <0.001
Somnolence 139/5360 91/4542 1.23 (0.94 to 1.62), 0.13 0.005 (−0.001 to 0.01), 0.13
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 This discrepancy with our findings could be explained 
by the small sample size of their study (288 from four 
randomised controlled trials versus 10 347 from 35 ran-
domised controlled trials in our analysis).
Gibbons and Mann used pooled data from 17 ran-
domised controlled trials sponsored by Pfizer to exam-
ine neuropsychiatric adverse events associated with 
varenicline.10 Our study included industry and non- 
industry sponsored trials and more than twice the num-
ber of trials that they included. Their findings of no 
increased risk of suicidal events, depression, and agita-
tion are consistent with our study. Although the authors 
did not include references to the published literature 
for their included studies (which made cross referenc-
ing difficult), it is likely that we included most of their 
studies in our analysis.
Another meta-analysis examined the long term effi-
cacy and safety of varenicline in trials with a minimum 
follow-up period of 12 months.70 A meta-analysis of the 
main psychiatric related adverse effects (which com-
bined depressed mood, other mood disorders, bipolar 
disorder, delirium, suicidal and self injurious 
behaviours, adjustment disorders, and abnormal think-
ing into a single outcome) did not show a “significant 
increase of psychiatric side effects for varenicline com-
pared with placebo.”70 This meta-analysis, however, 
included only three trials, and the combined psychiat-
ric outcome was non-specific. The authors reported an 
increased risk of insomnia (relative risk 1.65, 95% confi-
dence interval 1.29 to 2.11), abnormal dreams (2.78, 2.07 
to 3.73), and sleep disturbance (2.09, 1.62 to 2.69) but no 
increased risk of irritability (1.14, 0.75 to 1.73), which is 
consistent with our findings.70
A previous Cochrane review examined the efficacy 
and tolerability of nicotine receptor partial agonists 
including varenicline.16 Trials were excluded if partici-
pants used smokeless tobacco or if there was less than 
six months of follow-up. In addition to the efficacy out-
comes, meta-analyses were performed for the most 
commonly reported adverse events: nausea, insomnia, 
abnormal dreams, and headache. Findings were consis-
tent with our study for insomnia (relative risk 1.62, 95% 
confidence interval 1.40 to 1.88) and abnormal dreams 
(2.91, 2.34 to 3.62).16 The Cochrane review did not report 
any treatment emergent deaths. Although we used a 
broader definition of deaths in our analysis by includ-
ing all deaths irrespective of whether or not we thought 
they were related to treatment, we did not find an 
increased risk of death in the varenicline group.
strengths and limitations
To the best of our knowledge, this is the most compre-
hensive published systematic review (and meta-analy-
sis) of neuropsychiatric effects associated with use of 
varenicline. Compared with the previous Cochrane 
review,16 our analysis included 16 additional trials for the 
meta-analysis of the risk of insomnia events and 23 addi-
tional trials for the pooled analysis of abnormal dreams.
The choice of summary statistics for meta-analyses of 
rare events caused controversy (about whether the Peto 
odds ratio should be reported instead of risk differ-
ences) when it led to conflicting findings from two sys-
tematic reviews examining the risk of cardiovascular 
side effects associated with varenicline use.71 72 We pres-
ent results using both measures: a relative measure 
(Peto odds ratio and sensitivity analyses with fixed and 
random effects odds ratios) as well as an absolute mea-
sure (risk difference). Findings were consistent for all 
examined outcomes.
Many study authors did not specify the actual dates 
that adverse events were reported so we included all 
reported events; this decision would have increased the 
likelihood of obtaining reports of rare adverse events. 
We contacted authors for all of our included trials to 
check the data extracted on adverse events and for 
study protocols and other information to adequately 
assess the risk of bias in the studies. We had a high 
response rate (75%).
There are some limitations. Firstly, in this analysis we 
used study level data instead of individual level data so 
we were unable to determine whether differences in the 
adverse events were because of greater quit rates in the 
varenicline group relative to placebo. Secondly, because 
of the small number of suicides and attempted suicide 
reported (n=6), we cannot rule out major beneficial or 
adverse effects of varenicline for this outcome (Peto odds 
ratio 1.67, 95% confidence interval 0.33 to 8.57). Thirdly, 
there was potential for heterogeneity in the reporting of 
adverse events. Authors used a range of methods to 
record adverse events including self report, open ended 
questions, structured questionnaires, side effect check-
lists, and case reports coded to the Medical Dictionary for 
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Regulatory Activities (MedDRA, www.meddra.org). All of 
the industry sponsored trials coded adverse events using 
MedDRA. Fourthly, we excluded two studies69 73 from the 
review as the maximum dose of varenicline used in these 
studies was only 1 mg once a day—that is, half of the rec-
ommended maximum dose. Hong and colleagues exam-
ined varenicline treatment in 20 smokers and 15 
non-smokers with schizophrenia or schizoaffective disor-
der and found no evidence that varenicline worsened 
psychiatric symptoms in these patients.69 Mocking and 
colleagues studied the effects of varenicline on emotional 
and cognitive processing in 21 healthy adult non-smokers 
and concluded that it did not cause problems in emo-
tional processing or impulsivity, providing less support 
for a possible depressogenic effect of varenicline.73 Fur-
thermore, a secondary analysis, which included all doses 
of varenicline in the original trials and these two excluded 
randomised controlled trials, produced similar findings 
to our main analysis (see appendix 6).
We tried to minimise reporting bias by including all 
events (such as deaths) reported regardless of whether or 
not we considered them to be related to treatment. It is still 
possible, however, that reporting bias could have occurred 
as for certain trials, where the corresponding authors did 
not respond to our requests for additional information, we 
could not determine whether a lack of reporting of deaths 
in the published paper was synonymous with no deaths. 
It was difficult to interpret the funnel plots to assess 
whether publication bias might be present as most trials 
were efficacy trials and were not performed solely to deter-
mine the incidence of psychiatric adverse events.
Additionally, smoking cessation has been shown to 
have a positive impact on mental health outcomes with 
a reduction in depression and anxiety compared with 
those who continue to smoke.74 Patients prescribed 
varenicline were reported to have an approximately 
threefold increased chance of quitting smoking com-
pared with those given placebo (odds ratio 2.88, 95% 
confidence interval 2.40 to 3.47)4; this could explain the 
reduction in anxiety observed in this meta-analysis.
Lastly, half of the trials were sponsored by Pfizer, the 
manufacturers of varenicline. Although previous 
research with nicotine replacement therapy has shown 
that industry sponsored trials were more likely than 
other trials to report outcomes that were favourable to 
the study sponsor,14 we did not find any evidence for 
differences in depression and suicidal ideation for 
industry versus non industry sponsored trials (P=0.386 
and P=0.380, respectively, for interaction). In addition, 
all of the industry sponsored trials were assessed over-
all as having a low risk of bias.
Conclusions and clinical implications
Based on this comprehensive systematic review of pub-
lished randomised controlled trials, there is no evi-
dence of an increased risk of depression, suicidal 
behaviour (that is, suicide or attempted suicide, sui-
cidal ideation), and death from any cause associated 
with treatment with varenicline. Varenicline users, 
however, have an increased risk of abnormal dreams, 
insomnia, and sleep disturbances, which are consistent 
with findings from other studies and previously docu-
mented commonly reported side effects of varenicline 
(www.chantix.com). We reported our findings using 
two summary statistics (a relative measure and an abso-
lute measure) and observed consistency with both 
methods. This meta-analysis adds to previous research 
(observational and experimental) that found no evi-
dence for increased suicidal behaviour or depression 
with varenicline, the most effective drug for smoking 
cessation.4 The dangers of smoking are well docu-
mented, and the health benefits of stopping smoking 
are well known. Our analysis suggests that the benefits 
of varenicline for smoking cessation outweigh the as yet 
unproved risks of suicidal behaviour. In the UK, vareni-
cline is recommended alongside bupropion and nico-
tine replacement therapy as first line treatment for 
smoking cessation.75 Therefore, the reduction in vareni-
cline prescribing in the UK should be as much a cause 
for concern to clinicians, regulatory agencies, and 
 policy makers as the unfounded fears regarding vareni-
cline’s association with suicidal behaviour.
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17/256
1/40
8/31
5/249
163/5356
Treatment
1/123
17/604
1/340
4/121
7/344
4/126
2/124
2/155
0/7
3/350
5/218
2/111
1/55
0/54
1/38
2/39
4/198
5/251
3/43
5/165
2/135
2/9
20/42
7/33
6/101
14/106
1/5
13/269
1/47
2/29
2/245
139/4487
Control
No of events/total
fig 5 | forest plot of risk of depression events (mantel-Haenszel risk difference) associated 
with varenicline use in 31 placebo controlled randomised trials
table 5 | Comparison of Peto, fixed effects, and random effects odds ratios (Or) for 
insomnia, sleep disorders, and abnormal dreams in people treated with varenicline
neuropsychiatric 
adverse event
no of events/no treated
Odds ratio (95% Ci)*
test for 
heterogeneity (%)varenicline group Placebo group
insomnia
Peto OR 679/5621 379/4762 1.56 (1.36 to 1.78) 0
Fixed effects OR 679/5621 379/4762 1.56 (1.35 to 1.79) 0
Random effects OR 679/5621 379/4762 1.56 (1.35 to 1.79) 0
sleep disorders
Peto OR 211/5081 123/4284 1.63 (1.29 to 2.07) 0
Fixed effects OR 211/5081 123/4284 1.57 (1.22 to 2.03) 0
Random effects OR 211/5081 123/4284 1.57 (1.22 to 2.03) 0
abnormal dreams 
Peto OR 603/5606 224/4741 2.38 (2.05 to 2.77) 22.3
Fixed effects OR 603/5606 224/4741 2.37 (1.99 to 2.82) 31.6
Random effects OR 603/5606 224/4741 2.36 (1.87 to 2.98) 31.6
*All P<0.001.
RESEARCH
10 doi: 10.1136/bmj.h1109 | BMJ 2015;350:h1109 | the bmj
13 Miller M, Hemenway D, Rimm E. Cigarettes and suicide: a prospective 
study of 50,000 men. Am J Public Health 2000;90:768–73.
14 Etter JF, Burri M, Stapleton J. The impact of pharmaceutical company 
funding on results of randomized trials of nicotine replacement 
therapy for smoking cessation: a meta-analysis. Addiction 
2007;102:815–22.
15 Prescribing and Primary Care team Health and Social Care Information 
Centre. Prescription cost analysis, England, 2013. Health and Social 
Care Information Centre, 2014.
16 Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for 
smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103.
17 Higgins JPT, Altman DG. Assessing risk of bias in included studies. 
Cochrane handbook for systematic reviews of interventions. John 
Wiley, 2008:187–241.
18 Harris R, Bradburn M, Deeks J, Harbord R, Altman D, Sterne J. metan: 
fixed- and random-effects meta-analysis. Stata J 2008;8:3–28.
19 Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A. Much ado about 
nothing: a comparison of the performance of meta-analytical 
methods with rare events. Stat Med 2007;26:53–77.
20 Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring 
inconsistency in meta-analyses. BMJ 2003;327:557–60.
21 Higgins JPT, Deeks JJ, Altman DG. Special topics in statistics. Cochrane 
handbook for systematic reviews of interventions. John Wiley, 
2008:481–529.
22 Sterne JAC, Harbord RM. Funnel plots in meta-analysis. Stata J 
2004;4:127–41.
23 Harbord RM, Harris RJ, Sterne JAC. Updated tests for small-study 
effects in meta-analyses. Stata J 2009;9:197–210.
24 Anthenelli RM, Morris C, Ramey TS, Dubrava SJ, Tsilkos K, Russ C, et al. 
Effects of varenicline on smoking cessation in adults with stably 
treated current or past major depression: a randomized trial. Ann 
Intern Med 2013;159:390–400.
25 Bolliger CT, Issa JS, Posadas-Valay R, Safwat T, Abreu P, Correia EA, 
et al. Effects of varenicline in adult smokers: a multinational, 24-week, 
randomized, double-blind, placebo-controlled study. Clin Ther 
2011;33:465–77.
26 Brandon TH, Drobes DJ, Unrod M, Heckman BW, Oliver JA, Roetzheim 
RC, et al. Varenicline effects on craving, cue reactivity, and smoking 
reward. Psychopharmacology (Berl) 2011;218:391–403.
27 Burstein AH, Fullerton T, Clark DJ, Faessel HM. Pharmacokinetics, 
safety, and tolerability after single and multiple oral doses of 
varenicline in elderly smokers. J Clin Pharmacol 2006;46:1234–40.
28 Cinciripini PM, Robinson JD, Karam-Hage M, Minnix JA, Lam C, Versace 
F, et al. Effects of varenicline and bupropion sustained-release use 
plus intensive smoking cessation counseling on prolonged 
abstinence from smoking and on depression, negative affect, and 
other symptoms of nicotine withdrawal. JAMA Psychiatry 
2013;70:522–33.
29 Ebbert JO, Croghan IT, Severson HH, Schroeder DR, Hays JT. A pilot 
study of the efficacy of varenicline for the treatment of smokeless 
tobacco users in Midwestern United States. Nicotine Tob Res 
2011;13:820–6.
30 Evins AE, Cather C, Pratt SA, Pachas GN, Hoeppner SS, Goff DC, et al. 
Maintenance treatment with varenicline for smoking cessation in 
patients with schizophrenia and bipolar disorder: a randomized 
clinical trial. JAMA 2014;311:145–54.
31 Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and 
tolerability of varenicline in healthy adolescent smokers: 
a multicenter, randomized, double-blind, placebo-controlled, 
parallel-group study. Clin Ther 2009;31:177–89.
32 Fagerstrom K, Gilljam H, Metcalfe M, Tonstad S, Messig M. Stopping 
smokeless tobacco with varenicline: randomised double blind 
placebo controlled trial. BMJ 2010;341:c6549.
33 Fatemi SH, Yousefi MK, Kneeland RE, Liesch SB, Folsom TD, Thuras PD. 
Antismoking and potential antipsychotic effects of varenicline 
in subjects with schizophrenia or schizoaffective disorder: 
a double-blind placebo and bupropion-controlled study. Schizophr 
Res 2013;146:376–8.
34 Garza D, Murphy M, Tseng LJ, Riordan HJ, Chatterjee A. A double-blind 
randomized placebo-controlled pilot study of neuropsychiatric 
adverse events in abstinent smokers treated with varenicline or 
placebo. Biol Psychiatry 2011;69:1075–82.
35 Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. 
Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial 
agonist, vs sustained-release bupropion and placebo for smoking 
cessation: a randomized controlled trial. JAMA 2006;296:47–55.
36 Hughes JR, Rennard SI, Fingar JR, Talbot SK, Callas PW, Fagerstrom KO. 
Efficacy of varenicline to prompt quit attempts in smokers not 
currently trying to quit: a randomized placebo-controlled trial. 
Nicotine Tob Res 2011;13:955–64.
37 Jorenby DE, Hays JT, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, et al. 
Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine 
receptor partial agonist, vs placebo or sustained-release bupropion 
for smoking cessation: a randomized controlled trial. JAMA 
2006;296:56–63.
38 Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, et al. 
A double-blind, placebo-controlled trial assessing the efficacy of 
varenicline tartrate for alcohol dependence. J Addict Med 
2013;7:277–86.
39 McClure EA, Vandrey RG, Johnson MW, Stitzer ML. Effects of 
varenicline on abstinence and smoking reward following a 
programmed lapse. Nicotine Tob Res 2013;15:139–48.
40 McKee SA, Harrison EL, O’Malley SS, Krishnan-Sarin S, Shi J, Tetrault 
JM, et al. Varenicline reduces alcohol self-administration in 
heavy-drinking smokers. Biol Psychiatry 2009;66:185–90.
41 Meszaros ZS, Abdul-Malak Y, Dimmock JA, Wang D, Ajagbe TO, Batki 
SL. Varenicline treatment of concurrent alcohol and nicotine 
dependence in schizophrenia: a randomized, placebo-controlled pilot 
trial. J Clin Psychopharmacol 2013;33:243–7.
42 Mitchell JM, Teague CH, Kayser AS, Bartlett SE, Fields HL. Varenicline 
decreases alcohol consumption in heavy-drinking smokers. 
Psychopharmacology (Berl) 2012;223:299–306.
43 Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves 
KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic 
acetylcholine receptor partial agonist, in a 12-week, randomized, 
placebo-controlled, dose-response study with 40-week follow-up for 
smoking cessation in Japanese smokers. Clin Ther 2007;29:1040–56.
44 Niaura R, Hays JT, Jorenby DE, Leone FT, Pappas JE, Reeves KR, et al. 
The efficacy and safety of varenicline for smoking cessation using a 
flexible dosing strategy in adult smokers: a randomized controlled 
trial. Curr Med Res Opin 2008;24:1931–41.
45 Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, 
et al. Smoking cessation with varenicline, a selective alpha4beta2 
nicotinic receptor partial agonist: results from a 7-week, randomized, 
placebo- and bupropion-controlled trial with 1-year follow-up. Arch 
Intern Med 2006;166:1561–8.
46 Oncken C, Gonzales D, Nides M, Rennard S, Watsky E, Billing CB, et al. 
Efficacy and safety of the novel selective nicotinic acetylcholine 
receptor partial agonist, varenicline, for smoking cessation. Arch 
Intern Med 2006;166:1571–7.
47 Plebani JG, Lynch KG, Yu Q, Pettinati HM, O’Brien CP, Kampman KM. 
Results of an initial clinical trial of varenicline for the treatment of 
cocaine dependence. Drug Alcohol Depend 2012;121:163–6.
48 Plebani JG, Lynch KG, Rennert L, Pettinati HM, O’Brien CP, Kampman 
KM. Results from a pilot clinical trial of varenicline for the treatment of 
alcohol dependence. Drug Alcohol Depend 2013;133:754–8.
49 Poling J, Rounsaville B, Gonsai K, Severino K, Sofuoglu M. The safety 
and efficacy of varenicline in cocaine using smokers maintained on 
methadone: a pilot study. Am J Addict 2010;19:401–8.
50 Rennard S, Hughes J, Cinciripini PM, Kralikova E, Raupach T, Arteaga C, 
et al. A randomized placebo-controlled trial of varenicline for smoking 
cessation allowing flexible quit dates. Nicotine Tob Res 
2012;14:343–50.
51 Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. 
Efficacy and safety of varenicline for smoking cessation in patients 
with cardiovascular disease: a randomized trial. Circulation 
2010;121:221–9.
52 Shim JC, Jung DU, Jung SS, Seo YS, Cho DM, Lee JH, et al. Adjunctive 
varenicline treatment with antipsychotic medications for cognitive 
impairments in people with schizophrenia: a randomized 
double-blind placebo-controlled trial. Neuropsychopharmacology 
2012;37:660–8.
53 Stein MD, Caviness CM, Kurth ME, Audet D, Olson J, Anderson BJ. 
Varenicline for smoking cessation among methadone-maintained 
smokers: a randomized clinical trial. Drug Alcohol Depend 
2013;133:486–93.
54 Steinberg MB, Randall J, Greenhaus S, Schmelzer AC, Richardson DL, 
Carson JL. Tobacco dependence treatment for hospitalized smokers: 
a randomized, controlled, pilot trial using varenicline. Addic Behav 
2011;36:1127–32.
55 Tashkin DP, Rennard S, Hays JT, Ma W, Lawrence D, Lee TC. Effects of 
varenicline on smoking cessation in patients with mild to moderate 
COPD: a randomized controlled trial. Chest 2011;139:591–9.
56 Tonnesen P, Mikkelsen K. Varenicline to stop long-term nicotine 
replacement use: a double-blind, randomized, placebo-controlled 
trial. Nicotine Tob Res 2013;15:419–27.
57 Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR, 
et al. Effect of maintenance therapy with varenicline on smoking 
cessation: a randomized controlled trial. JAMA 2006;296:64–71.
58 Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB, Jr., et al. 
A randomized, placebo-controlled trial of varenicline, a selective 
alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new 
therapy for smoking cessation in Asian smokers. Clin Ther 
2007;29:1027–39.
59 Wang C, Xiao D, Chan KPW, Pothirat C, Garza D, Davies S. Varenicline 
for smoking cessation: A placebo-controlled, randomized study. 
Respirology 2009;14:384–92.
60 Weiner E, Buchholz A, Coffay A, Liu F, McMahon RP, Buchanan RW, 
et al. Varenicline for smoking cessation in people with schizophrenia: 
a double blind randomized pilot study. Schizophr Res 2011;129:94–5.
RESEARCH
11the bmj | BMJ 2015;350:h1109 | doi: 10.1136/bmj.h1109
61 Williams K, Reeves K, Billing C, Pennington A, Gong J. A double-blind 
study evaluating the long-term safety of varenicline for smoking 
cessation. Curr Med Res Opin 2007;23:793–801.
62 Williams JM, Anthenelli RM, Morris CD, Treadow J, Thompson JR, Yunis 
C, et al. A randomized, double-blind, placebo-controlled study 
evaluating the safety and efficacy of varenicline for smoking cessation 
in patients with schizophrenia or schizoaffective disorder. J Clin 
Psychiatry 2012;73:654–60.
63 Wong J, Abrishami A, Yang Y, Zaki A, Friedman Z, Selby P, et al. A 
perioperative smoking cessation intervention with varenicline: 
a double-blind, randomized, placebo-controlled trial. Anesthesiology 
2012;117:755–64.
64 Zesiewicz TA, Greenstein PE, Sullivan KL, Wecker L, Miller A, Jahan I, 
et al. A randomized trial of varenicline (Chantix) for the treatment of 
spinocerebellar ataxia type 3. Neurology 2012;78:545–50.
65 Zhao Q, Schwam E, Fullerton T, O’Gorman M, Burstein AH. 
Pharmacokinetics, safety, and tolerability following multiple oral 
doses of varenicline under various titration schedules in elderly 
nonsmokers. J Clin Pharmacol 2011;51:492–501.
66 Chengappa KN, Perkins KA, Brar JS, Schlicht PJ, Turkin SR, Hetrick ML, 
et al. Varenicline for smoking cessation in bipolar disorder: a 
randomized, double-blind, placebo-controlled study. J Clin Psychiatry 
2014;75:765–72.
67 Gonzales D, Hajek P, Pliamm L, Nackaerts K, Tseng LJ, McRae TD, et al. 
Retreatment with varenicline for smoking cessation in smokers who 
have previously taken varenicline: a randomized, placebo-controlled 
trial. Clin Pharmacol Ther 2014;96:390–6.
68 Kishi T, Iwata N. Varenicline for smoking cessation in people with 
schizophrenia: systematic review and meta-analysis. Eur Arch 
Psychiatry Clin Neurosci 2014 Oct 5 [Epub ahead of print].
69 Hong LE, Thaker GK, McMahon RP, Summerfelt A, Rachbeisel J, Fuller 
RL, et al. Effects of moderate-dose treatment with varenicline on 
neurobiological and cognitive biomarkers in smokers and 
nonsmokers with schizophrenia or schizoaffective disorder. Arch Gen 
Psychiatry 2011;68:1195–206.
70 Huang Y, Li W, Yang L, Jiang Y, Wu Y. Long-term efficacy and safety of 
varenicline for smoking cessation: a systematic review and 
meta-analysis of randomized controlled trials. J Public Health 
2012;20:355–65.
71 Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse 
cardiovascular events associated with varenicline: a systematic 
review and meta-analysis. CMAJ 2011;183:1359–66.
72 Prochaska JJ, Hilton JF. Risk of cardiovascular serious adverse events 
associated with varenicline use for tobacco cessation: systematic 
review and meta-analysis. BMJ 2012;344:e2856.
73 Mocking RJ, Patrick Pflanz C, Pringle A, Parsons E, McTavish SF, Cowen 
PJ, et al. Effects of short-term varenicline administration on emotional 
and cognitive processing in healthy, non-smoking adults: 
a randomized, double-blind, study. Neuropsychopharmacology 
2013;38:476–84.
74 Taylor G, McNeill A, Girling A, Farley A, Lindson-Hawley N, Aveyard P. 
Change in mental health after smoking cessation: systematic review 
and meta-analysis. BMJ 2014;348:g1151.
75 Smoking cessation services in primary care, pharmacies, local 
authorities and workplaces, particularly for manual working groups, 
pregnant women and hard to reach communities. NICE public health 
guidance 10. National Institute for Health and Care Excellence, 2008.
© BMJ Publishing Group Ltd 2015
Appendix 1: Search strategy to identify relevant articles 
in Medline
Appendix 2: Further characteristics of included ran-
domised controlled trials
Appendix 3: Forest plots for secondary outcomes
Appendix 4: Subgroup analyses
Appendix 5: Funnel plots 
Appendix 6: Summary of Peto odds ratios, risk differ-
ences, and 95% confidence intervals for neuropsychiat-
ric events
